Optinose Expects XHANCE Net Revenues For FY24 To Be Between $85M-$95M; Sees Average XHANCE Net Revenue Per Prescription To Exceed $230 (Prior View: $220)

5/14/24 7:07:15 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $OPTN alert in real time by email

Operating Expenses
The Company expects total GAAP operating expenses (selling, general & administrative expenses and research & development expenses) for 2024 to be between $95.0 to $101.0 million, of which the Company expects stock-based compensation to be approximately $6.0 million.

Net Income from Operations
The Company expects to product positive income from operations (GAAP) for full year 2025.

Get the next $OPTN alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$OPTN

Date	Price Target	Rating	Analyst
3/11/2024	$5.00	Buy	H.C. Wainwright
8/21/2023	$3.00	Buy	Lake Street
10/21/2022	$5.00	Buy	Jefferies

More analyst ratings

$OPTN
Leadership Updates

Live Leadership Updates

Optinose Appoints Terry Kohler as Chief Financial Officer
YARDLEY, Pa., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the appointment of Terry Kohler as Chief Financial Officer. Mr. Kohler was most recently the Chief Financial Officer for Verrica Pharmaceuticals, a dermatology therapeutics company, where he supported commercial preparations for the launch of a topical treatment for molluscum contagiosum and research and development pipeline investments. Mr. Kohler is an experienced biotech finance leader with over 20 years of business experience. "We are pleased to add Terry to our leadership team to help guide
10/7/24 4:59:53 PM ET
$OPTN
Biotechnology: Pharmaceutical Preparations
Health Care
Optinose Announces CEO Transition and Business Update
YARDLEY, Pa., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Peter Miller has stepped down as Chief Executive Officer and Board member, and that Ramy Mahmoud, MD, MPH has been appointed as Chief Executive Officer and Board member. In announcing his departure, Peter Miller shared, "It has been a privilege working with the amazing group of colleagues at Optinose. I am proud of all that we have accomplished and the impact we continue to make in our mission to improve patients' lives." During Mr. Miller's nearly 13 years as CEO, the Company experienced s
1/31/23 7:00:00 AM ET
$OPTN
Biotechnology: Pharmaceutical Preparations
Health Care
Optinose Appoints Paul Spence as Chief Commercial Officer
YARDLEY, Pa., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the appointment of Paul Spence as Chief Commercial Officer. Mr. Spence was most recently the Senior Vice President of the U.S. Commercial Organization at Nestlé Health Sciences where he built the commercial capabilities for the Aimmune Gastrointestinal and Food Allergy businesses. Mr. Spence has 30 years of experience in the life science and pharmaceuticals industry as a leader responsible for marketing, sales, market access, operations, and supply chain. Prior to joining Nestlé Health Sciences,
12/15/22 4:30:00 PM ET
$OPTN
Biotechnology: Pharmaceutical Preparations
Health Care

$OPTN
Financials

Live finance-specific insights

Optinose Reports Third Quarter 2024 Financial Results and Recent Operational Highlights
Company reports Q3 2024 XHANCE net revenue of $20.4 million, an increase of 3% compared to Q3 2023 Company reports positive inflection in new prescriptions of XHANCE starting in September Company decreases full year 2024 XHANCE net revenue guidance to be between $75.0 to $79.0 million and increases expected average net revenue per prescription guidance to be approximately $270 Company decreases full year 2024 operating expenses guidance to be between $90.0 to $93.0 million Conference call and webcast to be held today at 8:00 a.m. Eastern Time YARDLEY, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and
11/12/24 7:00:12 AM ET
$OPTN
Biotechnology: Pharmaceutical Preparations
Health Care
Optinose Announces Reporting Date for Third Quarter 2024 Financial Results
YARDLEY, Pa., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the third quarter 2024 and corporate updates, before market open, on Tuesday, November 12, 2024. Company to Host Conference CallMembers of the Company's leadership team will host a conference call to discuss financial results and corporate updates. The call is scheduled to start at 8:00 a.m. Eastern Time on Tuesday, November 12, 2024. Participants may access the conference call live via webcast by visiting the Investors section of Optinose's website
11/5/24 4:30:00 PM ET
$OPTN
Biotechnology: Pharmaceutical Preparations
Health Care
Optinose Announces Reporting Date for Second Quarter 2024 Financial Results
YARDLEY, Pa., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the second quarter 2024 and corporate updates, before market open, on Thursday, August 8, 2024. Company to Host Conference CallMembers of the Company's leadership team will host a conference call to discuss financial results and corporate updates. The call is scheduled to start at 8:00 a.m. Eastern Time on Thursday, August 8, 2024. Participants may access the conference call live via webcast by visiting the Investors section of Optinose's website at
8/2/24 8:30:00 AM ET
$OPTN
Biotechnology: Pharmaceutical Preparations
Health Care

$OPTN
Press Releases

Fastest customizable press release news feed in the world

Optinose Reports Third Quarter 2024 Financial Results and Recent Operational Highlights
Company reports Q3 2024 XHANCE net revenue of $20.4 million, an increase of 3% compared to Q3 2023 Company reports positive inflection in new prescriptions of XHANCE starting in September Company decreases full year 2024 XHANCE net revenue guidance to be between $75.0 to $79.0 million and increases expected average net revenue per prescription guidance to be approximately $270 Company decreases full year 2024 operating expenses guidance to be between $90.0 to $93.0 million Conference call and webcast to be held today at 8:00 a.m. Eastern Time YARDLEY, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and
11/12/24 7:00:12 AM ET
$OPTN
Biotechnology: Pharmaceutical Preparations
Health Care
Optinose Announces Reporting Date for Third Quarter 2024 Financial Results
YARDLEY, Pa., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the third quarter 2024 and corporate updates, before market open, on Tuesday, November 12, 2024. Company to Host Conference CallMembers of the Company's leadership team will host a conference call to discuss financial results and corporate updates. The call is scheduled to start at 8:00 a.m. Eastern Time on Tuesday, November 12, 2024. Participants may access the conference call live via webcast by visiting the Investors section of Optinose's website
11/5/24 4:30:00 PM ET
$OPTN
Biotechnology: Pharmaceutical Preparations
Health Care
Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
YARDLEY, Pa., Oct. 16, 2024 (GLOBE NEWSWIRE) -- OptiNose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that the company has granted a non-qualified stock option awards to purchase an aggregate of 185,000 shares of its common stock to eight new employees as an inducement material for accepting employment with OptiNose. The stock option awards were granted outside of the OptiNose, Inc. 2010 Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options were granted to the new employees on their respective hire dates (October 7, 2024, and October 14, 2024) with an exe
10/16/24 4:05:00 PM ET
$OPTN
Biotechnology: Pharmaceutical Preparations
Health Care

$OPTN
Market Insights

Live Market Insights

Optinose Announced That Xhance (Fluticasone Propionate) Has Been Added To Express Scripts' National Formularies, Including The National Preferred, Flex, And Basic Formularies
6/27/24 7:11:27 AM ET
$OPTN
Biotechnology: Pharmaceutical Preparations
Health Care
Why Doximity Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket
Shares of Doximity, Inc. (NYSE:DOCS) rose sharply in today's pre-market trading reported stronger-than-expected financial results for the fourth quarter on Thursday. Doximity's fourth-quarter revenue increased 6% year-over-year to $118.1 million, which beat the consensus estimate of $116.4 million, according to Benzinga Pro. The company reported adjusted earnings of 25 cents per share, beating analyst estimates of 20 cents per share. The company said it expects first-quarter revenue to be between $119.5 million and $120.5 million versus estimates of $119.23 million. Doximity shares jumped 13.7% to $27.00 in the pre-market trading session. Here are some other stocks moving in pre-
5/17/24 8:19:51 AM ET
$AKAN
$AMPG
$BLIN
$BRSH
Medicinal Chemicals and Botanical Products
Health Care
Telecommunications Equipment
Telecommunications
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Scorpius Holdings (AMEX:SCPX) shares rose 20.9% to $0.12 during Thursday's after-market session. The market value of their outstanding shares is at $4.3 million. Kintara Therapeutics (NASDAQ:KTRA) stock increased by 19.22% to $0.17. The company's market cap stands at $6.7 million. The company's, Q3 earnings came out 2 days ago. Doximity (NYSE:DOCS) stock rose 11.4% to $26.45. The market value of their outstanding shares is at $4.9 billion. As per the news, the Q4 earnings report came out today. MEI Pharma (NASDAQ:MEIP) stock increased by 10.92% to $3.25. The company's market cap stands at $21.6 million. Akso Health Group (NASDAQ:AHG) stock increased by 9.36% to $0.69. The compan
5/16/24 4:31:13 PM ET
$AHG
$BSGM
$DOCS
$INBS
Business Services
Consumer Discretionary
EDP Services
Technology

Optinose Expects XHANCE Net Revenues For FY24 To Be Between $85M-$95M; Sees Average XHANCE Net Revenue Per Prescription To Exceed $230 (Prior View: $220)

Chat with this insight

Recent Analyst Ratings for $OPTN

$OPTN Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by OptiNose Inc.

Amendment: SEC Form SC 13G/A filed by OptiNose Inc.

Amendment: SEC Form SC 13G/A filed by OptiNose Inc.

$OPTN Leadership Updates

Live Leadership Updates

Optinose Appoints Terry Kohler as Chief Financial Officer

Optinose Announces CEO Transition and Business Update

Optinose Appoints Paul Spence as Chief Commercial Officer

$OPTN Financials

Live finance-specific insights

Optinose Reports Third Quarter 2024 Financial Results and Recent Operational Highlights

Optinose Announces Reporting Date for Third Quarter 2024 Financial Results

Optinose Announces Reporting Date for Second Quarter 2024 Financial Results

$OPTN Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

H.C. Wainwright initiated coverage on OptiNose with a new price target

Lake Street initiated coverage on OptiNose with a new price target

Jefferies resumed coverage on OptiNose with a new price target

$OPTN Press Releases

Fastest customizable press release news feed in the world

Optinose Reports Third Quarter 2024 Financial Results and Recent Operational Highlights

Optinose Announces Reporting Date for Third Quarter 2024 Financial Results

Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

$OPTN Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Financial Officer Kohler Terry was granted 150,000 shares (SEC Form 4)

SEC Form 3 filed by new insider Kohler Terry

Chief Legal Officer & Corp Sec Marino Michael F Iii sold $2,807 worth of shares (3,226 units at $0.87), decreasing direct ownership by 0.59% to 547,238 units (SEC Form 4)

$OPTN SEC Filings

SEC Form SCHEDULE 13G filed by OptiNose Inc.

SEC Form 10-Q filed by OptiNose Inc.

OptiNose Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

$OPTN Market Insights

Live Market Insights

Optinose Announced That Xhance (Fluticasone Propionate) Has Been Added To Express Scripts' National Formularies, Including The National Preferred, Flex, And Basic Formularies

Why Doximity Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket

12 Health Care Stocks Moving In Thursday's After-Market Session

Recent Analyst Ratings for
$OPTN

$OPTN
Large Ownership Changes

$OPTN
Leadership Updates

$OPTN
Financials

$OPTN
Analyst Ratings

$OPTN
Press Releases

$OPTN
Insider Trading

$OPTN
SEC Filings

$OPTN
Market Insights